Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure

C.N. Harrison, N. Schaap, A.M. Vannucchi, J.J. Kiladjian, E. Jourdan, R.T. Silver, H.C. Schouten, F. Passamonti, S. Zweegman, M. Talpaz, S. Verstovsek, S. Rose, J. Shen, T. Berry, C. Brownstein, R.A. Mesa

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)594-603
Number of pages10
JournalAmerican Journal of Hematology
Volume95
Issue number6
DOIs
Publication statusPublished - 1 Jun 2020

Keywords

  • available therapy
  • double-blind
  • efficacy
  • encephalopathy
  • inhibitor fedratinib
  • open-label
  • outcomes
  • phase-3
  • safety
  • sar302503
  • EFFICACY
  • SAFETY
  • OPEN-LABEL
  • PHASE-3
  • ENCEPHALOPATHY
  • DOUBLE-BLIND
  • SAR302503
  • OUTCOMES
  • INHIBITOR FEDRATINIB
  • AVAILABLE THERAPY

Cite this